Effect of orally administered monoclonal antibody on persistent Cryptosporidium parvum infection in scid mice

Abstract

scid mice, persistently infected after exposure to 107 Cryptosporidium parvum oocysts, were treated daily for 14 to 17 days with 0.4 mg of monoclonal antibody (mAb) 17.41 administered by the oral route. Mice receiving

Effect of spleen cell populations on resolution of Cryptosporidium parvum infection in SCID mice

“…During some experiments, a second method for evaluating infection was also performed. Feces from individual mice were collected and analyzed for the presence and number of C. parvum oocysts as previously described (27).…”

Enteral human serum immunoglobulin treatment of cryptosporidiosis in mice with severe combined immunodeficiency

“…given to newborn mice before or shortly after infection decrease infectivity scores in the intestines (1,5,19,25). Similarly, oral treatment with an IgM MAb (MAb 17.41) that reacts to multiple C. parvum antigens decreases the fecal excretion of oocysts and the number of cryptosporidia in the intestines of adult nude and scid mice with established infection (2,18). However, oral therapy with this MAb does not decrease the intensity of infection in the pyloroduodenal junctions or biliary tracts of the mice and does not eradicate infection in the intestines.…”

SCID mice and the study of parasitic disease

“…This model of C. parvum infection may prove very valuable for the testing of therapeutic agents against either intestinal or extraintestinal cryptosporidiosis. Indeed, the SCID mouse model has been used to show that orally administered polyclonal or monoclonal antibodies to C. parvum are capable of decreasing oocyst shedding and intestinal epithelial infection in chronically infected mice (68,72). These interventions fail to decrease the parasite load in the hepatobiliary system, suggesting that alternative methods of delivery or alternative modes of therapy will have to be explored to deal adequately with elimination of infection of these sites.…”